TB-500 (Thymosin Beta-4 Fragment)
Investigational synthetic Thymosin Beta-4 fragment (Ac-LKKTETQ), regenerative · Pre-filled pen
TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ) corresponding to the actin-binding region (residues 17–23) of Thymosin Beta-4, not the full-length protein. Laboratory studies indicate this motif carries much of Thymosin Beta-4's cell-migration and angiogenic activity, while other proposed effects, such as modulation of inflammation, are largely extrapolated from research on the full-length protein. Robust controlled human trials are lacking, so its recovery claims remain research-level.
Studied use areas
- Musculoskeletal and soft-tissue recovery (research context)
- Connective-tissue resilience
- Cell migration and tissue remodelling
- Angiogenesis and tissue perfusion
- Inflammation balance during recovery
Safety & status
- Investigational and not an approved medicine; controlled human safety data are lacking
- Prohibited in competitive sport under the WADA prohibited list
- Product purity and source quality can vary and affect risk
- Use only under qualified physician oversight
⚕ Clinical note: This card is educational and is not medical advice. TB-500 is investigational; any use must be individualised and determined by the treating physician.
Evidence: Investigational — mainly animal and cell data; no approved human indication · References: peer-reviewed regenerative-medicine and preclinical tissue-repair literature; EMA/MHRA regulatory-status information on unapproved peptides; sports anti-doping (WADA) prohibited-substance listings
